Dopamine Receptor Signaling and Current and Future Antipsychotic Drugs
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
All currently efficacious antipsychotic drugs have as part of their mechanism the ability to attenuate some or all of their signaling through the dopamine D2 receptor. More recently, the dopamine D1 receptor has been hypothesized to be a promising target for the treatment of negative and/or cognitive aspects of schizophrenia that are not improved by current antipsychotics. Although cAMP has been presumed to be the primary messenger for signaling through the dopamine receptors, the last decade has unveiled a complexity that has provided exciting avenues for the future discovery of antipsychotic drugs (APDs). We review the signaling mechanisms of currently approved APDs at dopamine D2 receptors, and note that aripiprazole is a compound that is clearly differentiated from other approved drugs. Although aripiprazole has been postulated to cause dopamine stabilization due to its partial D2 agonist properties, a body of literature suggests that an alternate mechanism, functional selectivity, is of primary importance. Finally, we review the signaling at dopamine D1 receptors, and the idea that drugs that activate D1 receptors may have use as APDs for improving negative and cognitive symptoms. We address the current state of drug discovery in the D1 area, and its relationship to novel signaling mechanisms. Our conclusion is that although the first APD targeting dopamine receptors was discovered more than a half-century ago, recent research advances offer the possibility that novel and/or improved drugs will emerge in the next decade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional anatomy of basal ganglia disorders
Albin, R. L., Young, A. B., & Penney, J. B. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90074-x · Cited by 5,353
Primate models of movement disorders of basal ganglia origin
DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824
Stereotaxic mapping of the monoamine pathways in the rat brain
Ungerstedt, U. (1971) · Acta Physiologica Scandinavica · doi:10.1111/j.1365-201x.1971.tb10998.x · Cited by 3,819
D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons
Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., & Sibley, D. R. (1990) · Science · doi:10.1126/science.2147780 · Cited by 2,967
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763 · cited 2×
“The common assumption was that drug effects on dopamine receptor-mediated cAMP signaling would be predictive of clinical action (see reviews, e.g., Beaulieu and Gainetdinov, 2011; Huang et al., 2001; Mailman, 2007).”
BackgroundDopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Neurotransmitters and neuromodulators in the basal ganglia
Graybiel, A. M. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90104-i · Cited by 1,576
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Seeman, P., & Lee, T. (1975) · Science · doi:10.1126/science.1145194 · Cited by 869 · cited 1×
“…schizophrenia were a response to hyperactive dopaminergic signaling, a hypothesis that was supported by the ability of APDs to block D2 receptors and the psychotic effects induced by dopaminergic drugs (Carlsson and Lindqvist, 1963; Creese et al., 1976; Seeman et al., 1975; Seeman and Lee, 1975).”
BackgroundLacey, M. G., Mercuri, N. B., & North, R. A. (1987) · The Journal of Physiology · doi:10.1113/jphysiol.1987.sp016787 · Cited by 614 · cited 1×
“D2-like receptors activate a G proteinregulated inwardly rectifying potassium channel (GIRK or Kir3), which modulates several potassium currents in various tissues (Greif et al., 1995; Lacey et al., 1987; Liu et al., 1994; Oxford and Wagoner, 1989).”
BackgroundDopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys
Arnsten, A. F. T., Cai, J. X., Murphy, B. L., & Goldman-Rakic, P. S. (1994) · Psychopharmacology · doi:10.1007/bf02245056 · Cited by 566 · cited 2×
“…as therapeutic targets for numerous CNS disorders, such as Parkinson’s disease (Mailman et al., 2001; Taylor et al., 1991), schizophrenia, learning and memory dysfunctions (Arnsten et al., 1994; Goldman-Rakic et al., 2004), and attention deficit hyperactivity disorder (Heijtz et al., 2007).”
BackgroundTargeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544 · cited 3×
“…as therapeutic targets for numerous CNS disorders, such as Parkinson’s disease (Mailman et al., 2001; Taylor et al., 1991), schizophrenia, learning and memory dysfunctions (Arnsten et al., 1994; Goldman-Rakic et al., 2004), and attention deficit hyperactivity disorder (Heijtz et al., 2007).”
BackgroundSesack, Sr., Aoki, C., & Pickel, V. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-01-00088.1994 · Cited by 461 · cited 1×
“…are predominately found postsynaptically (Levey et al., 1993), whereas the D2-like receptors are found postsynaptically on dopaminergic target neurons (Levey et al., 1993; Sesack et al., 1994) and as presynaptic and autoreceptors on dopamine neurons (L’hirondel et al., 1998; Mercuri et al., 1997).”
BackgroundCai, J. X., & Arnsten, A. F. T. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36983-6 · Cited by 285
Cell type–specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs
Bateup, H. S., Svenningsson, P., Kuroiwa, M., Gong, S., Nishi, A., Heintz, N., & Greengard, P. (2008) · Nature Neuroscience · doi:10.1038/nn.2153 · Cited by 233 · cited 1×
“Indeed, SKF81297 has been shown to improve recognition and memory by increasing the phosphorylation of CREB and DARPP32 in rat prefrontal cortex (Bateup et al., 2008; Hotte et al., 2006).”
BackgroundNagai, T., Takuma, K., Kamei, H., Ito, Y., Nakamichi, N., Ibi, D., Nakanishi, Y., Murai, M., Mizoguchi, H., Nabeshima, T., et al. (2007) · Learning & Memory · doi:10.1101/lm.461407 · Cited by 184 · cited 1×
“In addition, Nagai et al. (2007) revealed dose-dependent D1 activation of ERK1/2 in the mouse prefrontal cortex that was blocked by a D1 antagonist (but not a D2 antagonist).”
BackgroundWhite, F. J., Bednarz, L. M., Wachtel, S. R., Hjorth, S., & Brooderson, R. J. (1988) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(88)90442-x · Cited by 177
Stahl, S. M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1101 · Cited by 143 · cited 1×
“Although the compound has effects on several other receptors, many of the leading researchers/clinicians in schizophrenia biology have taken to calling aripiprazole the first “dopamine stabilizer” because of its D2 partial agonist properties (Lieberman, 2004; Stahl, 2001; Tamminga, 2002).”
BackgroundMottola, D. M., Kilts, J. D., Lewis, M. M., Connery, H. S., Walker, Q. D., Jones, S. R., Booth, R. G., Hyslop, D. K., Piercey, M., Wightman, R. M., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1166 · Cited by 123
Self-citationMotor Dysfunction in Type 5 Adenylyl Cyclase-null Mice
Iwamoto, T., Okumura, S., Iwatsubo, K., Kawabe, J.-I., Ohtsu, K., Sakai, I., Hashimoto, Y., Izumitani, A., Sango, K., Ajiki, K., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300075200 · Cited by 118 · cited 1×
“Signaling—Non-cyclase D1–mediated signaling clearly occurs (Leonard et al., 2003a; Leonard et al., 2003b; Mailman et al., 1986a), and evidence for a cAMP/PKA-independent signaling pathway has been shown in studies of adenylate cyclase V deficient mice (Iwamoto et al., 2003).”
Background
Cited by
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
Wang, H., Xu, J., Lazarovici, P., Quirion, R., & Zheng, W. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00255 · Cited by 436
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Peripheral and Central Effects of Circulating Catecholamines
William Tank, A., & Lee Wong, D. (2015) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2015.tb00599.x · Cited by 106
“DA receptors are all members of the G-protein-coupled receptor family (for recent reviews see (7,10).”
Kang, X.-L., Zhang, J.-Y., Wang, D., Zhao, Y.-M., Han, X.-L., Wang, J.-X., & Zhao, X.-F. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008331 · Cited by 96
Metadata
- Authors
- Boyd, K. N., & Mailman, R. B.
- Venue
- Handbook of Experimental Pharmacology
- Publisher
- Springer Berlin Heidelberg
- Published
- 2012
- Issue
- 212
- Pages
- 53-86
- ISSN
- 0171-2004 (ISSN-L)
- 1865-0325
- OpenAlex
- W1830139488
- Cited by
- 107
- References
- 21
- FWCI
- 24.14
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.